Template:Amyl nitrite: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Amyl nitrite|{{fontcolor|#6C7B8B|Amyl nitrite}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Amyl nitrite|{{fontcolor|#6C7B8B|Amyl nitrite}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Amyl nitrite tablet<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite indications and usage|Indications and Usage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite contraindications|Contraindications]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite contraindications|Contraindications]] | ||
| Line 17: | Line 15: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite drug interactions|Drug Interactions]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite drug interactions|Drug Interactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite overdosage|Overdosage]] | ||
| Line 25: | Line 21: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite clinical pharmacology|Clinical Pharmacology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite how supplied storage and handling|How Supplied/Storage and Handling]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amyl nitrite how supplied storage and handling|How Supplied/Storage and Handling]] | ||
Latest revision as of 23:59, 30 January 2014
| Amyl nitrite |
|---|
| Amyl nitrite tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Overdosage |
| Description |
| Clinical Pharmacology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials |
| ClinicalTrials.gov |